{"id":"https://openalex.org/W3097196556","doi":"https://doi.org/10.1182/blood-2020-134924","title":"Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma","display_name":"Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma","publication_year":2020,"publication_date":"2020-11-04","ids":{"openalex":"https://openalex.org/W3097196556","doi":"https://doi.org/10.1182/blood-2020-134924","mag":"3097196556"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2020-134924","doi":"https://doi.org/10.1182/blood-2020-134924","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-134924","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5070118399","display_name":"Ariosto Siqueira Silva","orcid":"https://orcid.org/0000-0003-3237-9986","observed_orcids":["https://orcid.org/0000-0003-3237-9986"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ariosto Siqueira Silva","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060845150","display_name":"Rafael Renatino Canevarolo","orcid":"https://orcid.org/0000-0002-8722-8512","observed_orcids":["https://orcid.org/0000-0002-8722-8512"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rafael Renatino-Canevarolo","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014350127","display_name":"Mark B. Meads","orcid":"https://orcid.org/0009-0008-0259-1875","observed_orcids":["https://orcid.org/0009-0008-0259-1875"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark B. Meads","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Maria D Coelho Siqueira Silva","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Maria D Coelho Siqueira Silva","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012307401","display_name":"Praneeth Reddy Sudalagunta","orcid":"https://orcid.org/0000-0003-1283-9332","observed_orcids":["https://orcid.org/0000-0003-1283-9332"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Praneeth Reddy Sudalagunta","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5036862186","display_name":"Christopher L. Cubitt","orcid":"https://orcid.org/0000-0001-6343-7451","observed_orcids":["https://orcid.org/0000-0001-6343-7451"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Christopher Cubitt","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035860017","display_name":"Gabriel De Avila","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gabriel De Avila","raw_affiliation_strings":["Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5040771903","display_name":"Raghunandan Reddy Alugubelli","orcid":"https://orcid.org/0000-0002-4314-1204","observed_orcids":["https://orcid.org/0000-0002-4314-1204"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Raghunandan Reddy Alugubelli","raw_affiliation_strings":["Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Malignant Hematology, H Lee Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5079103673","display_name":"Amit Kulkarni","orcid":"https://orcid.org/0009-0000-4624-4789","observed_orcids":["https://orcid.org/0009-0000-4624-4789"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amit Kulkarni","raw_affiliation_strings":["M2GEN, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M2GEN, Tampa, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Melissa Mitchell","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Melissa Mitchell","raw_affiliation_strings":["M2GEN, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M2GEN, Tampa, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101790056","display_name":"Hongyue A. Dai","orcid":"https://orcid.org/0000-0002-6609-9141","observed_orcids":["https://orcid.org/0000-0002-6609-9141"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Hongyue Dai","raw_affiliation_strings":["M2GEN, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M2GEN, Tampa, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100360359","display_name":"Qi Zhang","orcid":"https://orcid.org/0000-0002-7918-8952","observed_orcids":["https://orcid.org/0000-0002-7918-8952"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qi Zhang","raw_affiliation_strings":["M2GEN, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M2GEN, Tampa, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5022286739","display_name":"Oliver\u00a0A. Hampton","orcid":"https://orcid.org/0000-0001-9164-1070","observed_orcids":["https://orcid.org/0000-0001-9164-1070"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Oliver Hampton","raw_affiliation_strings":["M2GEN, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"M2GEN, Tampa, FL","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5101606910","display_name":"X. Lucas Lu","orcid":"https://orcid.org/0000-0001-6905-6887","observed_orcids":["https://orcid.org/0000-0001-6905-6887"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xin Lu","raw_affiliation_strings":["AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5043585994","display_name":"Dimple Modi","orcid":"https://orcid.org/0000-0001-7059-843X","observed_orcids":["https://orcid.org/0000-0001-7059-843X"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dimple A. Modi","raw_affiliation_strings":["AbbVie Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103552874","display_name":"Monica Motwani","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Monica Motwani","raw_affiliation_strings":["AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031953045","display_name":"Jason G. Harb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jason Harb","raw_affiliation_strings":["AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057862805","display_name":"Jeremy A. Ross","orcid":"https://orcid.org/0000-0002-8458-7819","observed_orcids":["https://orcid.org/0000-0002-8458-7819"]},"institutions":[{"id":"https://openalex.org/I2948539688","display_name":"AbbVie (United States)","ror":"https://ror.org/02g5p4n58","country_code":"US","type":"company","lineage":["https://openalex.org/I2948539688"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jeremy A. Ross","raw_affiliation_strings":["AbbVie, Inc., North Chicago, IL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AbbVie, Inc., North Chicago, IL","institution_ids":["https://openalex.org/I2948539688"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053572690","display_name":"Kenneth H. Shain","orcid":"https://orcid.org/0000-0003-4178-8888","observed_orcids":["https://orcid.org/0000-0003-4178-8888"]},"institutions":[{"id":"https://openalex.org/I3019308854","display_name":"Moffitt Cancer Center","ror":"https://ror.org/01xf75524","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I3019308854"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Kenneth H. Shain","raw_affiliation_strings":["Moffitt Cancer Center, Tampa, FL"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Moffitt Cancer Center, Tampa, FL","institution_ids":["https://openalex.org/I3019308854"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5500,"currency":"USD","value_usd":5500},"apc_paid":null,"fwci":0.4732,"has_fulltext":false,"cited_by_count":3,"citation_normalized_percentile":{"value":0.66244764,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":95},"biblio":{"volume":"136","issue":"Supplement 1","first_page":"49","last_page":"50"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9951000213623047,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10294","display_name":"Cell death mechanisms and regulation","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12534","display_name":"Protein Degradation and Inhibitors","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/venetoclax","display_name":"venetoclax","score":0.9269999861717224},{"id":"https://openalex.org/keywords/navitoclax","display_name":"navitoclax","score":0.9980000257492065},{"id":"https://openalex.org/keywords/bet-inhibitors","display_name":"BET inhibitors","score":0.7289999723434448},{"id":"https://openalex.org/keywords/trail-receptor-agonists","display_name":"TRAIL receptor agonists","score":0.8349999785423279},{"id":"https://openalex.org/keywords/bcl-2-family-proteins","display_name":"Bcl-2 family proteins","score":0.7630000114440918},{"id":"https://openalex.org/keywords/mitochondrial-apoptosis","display_name":"mitochondrial apoptosis","score":0.5090000033378601},{"id":"https://openalex.org/keywords/extrinsic-apoptotic-pathway","display_name":"extrinsic apoptotic pathway","score":0.8659999966621399},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.6869999766349792},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.5870000123977661},{"id":"https://openalex.org/keywords/ex-vivo-drug-sensitivity","display_name":"ex vivo drug sensitivity","score":0.6140000224113464}],"concepts":[{"id":"https://openalex.org/C2778524551","wikidata":"https://www.wikidata.org/wiki/Q7227206","display_name":"Pomalidomide","level":4,"score":0.7022321820259094},{"id":"https://openalex.org/C2780225316","wikidata":"https://www.wikidata.org/wiki/Q7131441","display_name":"Panobinostat","level":5,"score":0.7010912895202637},{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.6818380355834961},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.6694967150688171},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.6415160298347473},{"id":"https://openalex.org/C26291073","wikidata":"https://www.wikidata.org/wiki/Q310484","display_name":"Ex vivo","level":3,"score":0.6237670183181763},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5701901912689209},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4924376904964447},{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.477989137172699},{"id":"https://openalex.org/C31573885","wikidata":"https://www.wikidata.org/wiki/Q304484","display_name":"Programmed cell death","level":3,"score":0.4603566527366638},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.44737282395362854},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.42363429069519043},{"id":"https://openalex.org/C2779878957","wikidata":"https://www.wikidata.org/wiki/Q5984881","display_name":"Ibrutinib","level":4,"score":0.4220947027206421},{"id":"https://openalex.org/C2781119759","wikidata":"https://www.wikidata.org/wiki/Q5222113","display_name":"Daratumumab","level":4,"score":0.41345447301864624},{"id":"https://openalex.org/C190283241","wikidata":"https://www.wikidata.org/wiki/Q14599311","display_name":"Apoptosis","level":2,"score":0.40237516164779663},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.28599783778190613},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.2556680142879486},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.21784016489982605},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.15507984161376953},{"id":"https://openalex.org/C2778305200","wikidata":"https://www.wikidata.org/wiki/Q174378","display_name":"Histone deacetylase","level":4,"score":0.10390302538871765},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.08400550484657288},{"id":"https://openalex.org/C64927066","wikidata":"https://www.wikidata.org/wiki/Q36293","display_name":"Histone","level":3,"score":0.0},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2020-134924","doi":"https://doi.org/10.1182/blood-2020-134924","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2020-134924","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4211003428","https://openalex.org/W3111654706","https://openalex.org/W3108156315","https://openalex.org/W2981091192","https://openalex.org/W2979326559","https://openalex.org/W2784192932","https://openalex.org/W2566048014","https://openalex.org/W2980435771","https://openalex.org/W3214827876","https://openalex.org/W2885967791"],"abstract_inverted_index":{"Introduction:":[0],"Despite":[1],"some":[2],"long-term":[3],"remissions,":[4],"eventual":[5],"drug":[6,179,211,425,582],"resistance":[7,328],"in":[8,15,38,68,83,87,139,165,194,259,334,382,403,435,448,491,529,573,644,658,677,696],"most":[9],"patients":[10,88,277],"remains":[11],"a":[12,73,96,120,215,326,377,494,589,771],"critical":[13],"obstacle":[14],"the":[16,49,90,112,147,153,230,260,404,538,557,645],"treatment":[17,776],"of":[18,24,31,42,48,77,169,185,218,232,361,418,431,460,524,552,559,581,706,723,759,777],"multiple":[19,100,140,170,778],"myeloma":[20,779],"(MM).":[21],"The":[22,390],"development":[23],"new":[25,586],"drugs/drug":[26],"combinations":[27,507],"with":[28,163,196,279,400,515],"novel":[29,495,503,590],"mechanisms":[30,580],"action":[32],"are":[33],"needed":[34],"for":[35,420,570,602,627,775],"continued":[36,571],"improvement":[37],"patient":[39,234,254,291,387,554],"outcomes.":[40],"Initiation":[41],"tumor":[43,235],"cell":[44,129,166],"death":[45,130,132],"via":[46,131],"activation":[47],"intrinsic":[50,113],"(mitochondrial)":[51],"and/or":[52],"extrinsic":[53],"(death":[54],"receptor)":[55],"apoptotic":[56,114],"signaling":[57,343],"pathways":[58,134],"has":[59],"been":[60],"shown":[61,160],"to":[62,110,228,298,330,364,413,439,562],"be":[63],"an":[64,383,703,720,756,782],"effective":[65,486],"therapeutic":[66],"strategy":[67,601],"MM.":[69,335,492],"Venetoclax":[70],"(Ven)":[71],"is":[72,95,119,136,325,484,770,780],"selective,":[74],"small-molecule":[75,97],"inhibitor":[76,149,157],"BCL-2":[78,102],"that":[79,98,127,481,501],"exhibits":[80],"clinical":[81,574],"activity":[82,162,333,430,447,457,470,477],"MM":[84,222,233,253,290,307,386,553],"cells,":[85],"particularly":[86],"harboring":[89,309],"t(11;14)":[91,369,391,436],"translocation.":[92],"Navitoclax":[93],"(Nav)":[94],"targets":[99],"antiapoptotic":[101],"family":[103],"proteins,":[104],"including":[105,199,264,508,588],"BCL-XL,":[106],"BCL-2,":[107],"and":[108,135,142,152,181,190,223,244,271,284,351,424,462,466,510,513,532,566,584,596,598,604],"BCL-W":[109],"initiate":[111],"pathway.":[115],"Eftozanermin":[116],"alfa":[117],"(Eftoza)":[118],"novel,":[121],"second":[122],"generation":[123],"TRAIL":[124],"receptor":[125,133,342],"agonist":[126],"induces":[128],"under":[137],"investigation":[138],"solid":[141],"heme":[143,171],"malignancies.":[144,172],"In":[145],"addition,":[146],"pan-BET":[148,482],"mivebresib":[150],"(Miv)":[151],"BDII":[154],"selective":[155],"BET":[156,489],"ABBV-744":[158,191,467],"have":[159],"synergistic":[161,504,536],"Ven":[164,299,331,365,401,509,531,595],"line":[167],"models":[168],"Results":[173],"reported":[174],"here":[175],"describe":[176],"ex":[177,209,261,300,366,405,428,445,471,505,547],"vivo":[178,210,262,301,406,429,446,506,548],"sensitivities":[180],"functional":[182,549],"genomic":[183,550],"analyses":[184,248,410],"Ven,":[186],"Nav,":[187],"Eftoza,":[188],"Miv,":[189],"alone":[192],"or":[193,204,518,668,687,708,725,761],"combination":[195,600],"standard-of-care":[197],"agents,":[198],"bortezomib,":[200],"carfilzomib,":[201],"panobinostat,":[202],"daratumumab,":[203,533,597],"pomalidomide.":[205],"Methods:":[206],"A":[207,368],"high-throughput":[208],"screening":[212],"assay":[213],"using":[214,376],"coculture":[216],"system":[217],"bone":[219],"marrow":[220],"(BM)-derived":[221],"stromal":[224],"cells":[225,236,308],"was":[226,373,396,433,451,499,527,535],"used":[227,500],"assess":[229],"sensitivity":[231,363,583],"(Figure":[237,543],"1A).":[238],"Paired":[239],"whole":[240],"exome":[241],"sequencing":[242,246],"(WES)":[243],"RNA":[245],"(RNA-seq)":[247],"were":[249,257,293,311,411,541],"performed.":[250],"Results:":[251],"Primary":[252],"specimens":[255,292,437,450,555],"(n=52)":[256],"evaluated":[258],"platform,":[263],"treatment-na\u00efve,":[265],"early":[266],"relapse":[267,273],"(1-3":[268],"prior":[269,275],"lines),":[270],"late":[272],"(4-8":[274],"lines)":[276],"treated":[278],"proteasome":[280,605],"inhibitors,":[281],"immunomodulatory":[282],"drugs,":[283],"monoclonal":[285],"antibodies.":[286],"As":[287],"expected,":[288],"t(11;14)-positive":[289],"more":[294,312,485],"sensitive":[295],"than":[296,314,487],"wildtype":[297,315],"(D":[302,316,441],"AUC,":[303,317,442],"-18.6,":[304],"P=0.002),":[305],"however":[306,473],"amp(1q)":[310],"resistant":[313],"+5.07,":[318],"P=0.032),":[319],"suggesting":[320,480],"MCL1":[321],"(1q21":[322],"gene":[323,370,393],"locus)":[324],"key":[327],"factor":[329],"single-agent":[332,469,522],"Gene":[336],"set":[337],"enrichment":[338,345],"analysis":[339,498],"identified":[340,502,585],"B-cell":[341],"(normalized":[344],"score":[346],"(NES),":[347],"1.96,":[348],"adjusted":[349,356],"P=0.010)":[350,357],"MYC":[352],"pathway":[353,409],"(NES,":[354],"1.95,":[355],"overexpression":[358],"as":[359],"predictors":[360],"increased":[362],"vivo.":[367],"expression":[371,394],"signature":[372,395],"also":[374,452],"generated":[375],"penalized":[378],"regression":[379],"model":[380],"approach":[381,561,577],"additional":[384,455],"MMWG/ORIEN":[385],"cohort":[388],"(n=155).":[389],"predictive":[392,416,568],"confirmed":[397,578],"by":[398,458],"correlation":[399],"AUC":[402],"model.":[407],"Additional":[408],"performed":[412],"identify":[414,563],"potential":[415,567,599],"markers":[417],"sensitivity/resistance":[419],"each":[421],"single":[422],"agent":[423],"combination.":[426],"Although":[427],"Nav":[432],"higher":[434,476],"compared":[438],"non-t(11;14)":[440,449],"-17.8,":[443],"P=0.011),":[444],"observed,":[453],"indicating":[454],"anti-MM":[456],"cotargeting":[459],"BCL-XL":[461],"BCL-2.":[463],"Both":[464],"Miv":[465,474],"showed":[468],"vivo,":[472],"demonstrated":[475,556],"(median":[478],"LD50=88.4nM),":[479],"inhibition":[483,490],"BDII-specific":[488],"Finally,":[493],"drug-combination":[496],"effect":[497],"panobinostat":[511],"(P=0.0013)":[512],"Eftoza":[514,603],"bortezomib":[516],"(P=1.8E-7)":[517],"carfilzomib":[519],"(P=7E-4).":[520],"Additionally,":[521],"induction":[523],"macrophage-mediated":[525],"phagocytosis":[526],"observed":[528],"both":[530],"which":[534],"when":[537],"2":[539],"drugs":[540,565],"combined":[542],"1B).":[544],"Conclusion:":[545],"An":[546],"screen":[551],"usefulness":[558],"this":[560,769],"candidate":[564],"biomarkers":[569],"evaluation":[572],"trials.":[575],"This":[576],"known":[579],"ones,":[587],"characterized":[591],"immune-mediated":[592],"synergy":[593],"between":[594],"inhibitors.":[606],"Figure":[607],"1":[608],"Disclosures":[609],"Siqueira":[610],"Silva:":[611],"Karyopharm:":[612,730],"Research":[613,616,619,630,635,731,736],"Funding;":[614,617,631,737],"NIH/NCI:":[615],"AbbVie:":[618,735],"Funding.":[620,636],"Kulkarni:M2GEN:":[621],"Current":[622,633,639,650,653,655,662,672,674,681,691,693],"Employment.":[623,651],"Mitchell:AbbVie:":[624],"Other:":[625,664,683],"payment":[626],"bioinformatics":[628],"analysis,":[629],"M2GEN:":[632,641],"Employment,":[634,654,663,673,682,692],"Dai:Cygnal":[637],"Therapeutics:":[638],"Employment;":[640],"Ended":[642],"employment":[643],"past":[646],"24":[647],"months.":[648],"Hampton:M2GEN:":[649],"Lu:AbbVie:":[652],"equity":[656,675,694],"holder":[657,676,695],"publicly-traded":[659,678,697],"company.":[660,679,698],"Modi:AbbVie:":[661],"may":[665,684],"own":[666],"stock":[667,669,686,688],"options.":[670,689],"Motwani:AbbVie:":[671],"Harb:AbbVie:":[680],"hold":[685],"Ross:AbbVie:":[690],"Shain:Celgene:":[699],"Honoraria,":[700,717,739,743,753],"Membership":[701,718,754],"on":[702,719,755],"entity's":[704,721,757],"Board":[705,722,758],"Directors":[707,724,760],"advisory":[709,726,762],"committees,":[710,727,763],"Speakers":[711,714,728,733,740,744,747,764],"Bureau;":[712,715,729,734,741,745,748],"GlaxoSmithKline:":[713],"Sanofi/Genzyme:":[716],"Funding,":[732],"Takeda:":[738],"Janssen:":[742],"Amgen:":[746],"Adaptive:":[749],"Consultancy,":[750],"Honoraria;":[751],"BMS:":[752],"Bureau.":[765],"OffLabel":[766],"Disclosure:":[767],"While":[768],"preclinical":[772],"study,":[773],"venetoclax":[774],"not":[781],"approved":[783],"indication":[784]},"counts_by_year":[{"year":2022,"cited_by_count":1},{"year":2021,"cited_by_count":2}],"updated_date":"2026-10-13T10:08:12.033832","created_date":"2020-11-09T00:00:00"}